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Macrophage-mediated delivery of light activated
nitric oxide prodrugs with spatial, temporal and
concentration control†
Michael A. Evans,‡abc Po-Ju Huang,‡a Yuji Iwamoto,d Kelly N. Ibsen,b Emory M. Chan,e
Yutaka Hitomi,d Peter C. Ford *a and Samir Mitragotri *bc
Nitric oxide (NO) holds great promise as a treatment for cancer hypoxia, if its concentration and localization
can be precisely controlled. Here, we report a “Trojan Horse” strategy to provide the necessary spatial,
temporal, and dosage control of such drug-delivery therapies at targeted tissues. Described is a unique
package consisting of (1) a manganese–nitrosyl complex, which is a photoactivated NO-releasing moiety
(photoNORM), plus Nd3+-doped upconverting nanoparticles (Nd-UCNPs) incorporated into (2)
biodegradable polymer microparticles that are taken up by (3) bone-marrow derived murine
macrophages. Both the photoNORM [Mn(NO)dpaqNO2]BPh4(dpaq
NO2 ¼ 2-[N,N-bis(pyridin-2-yl-methyl)]-
amino-N0-5-nitro-quinolin-8-yl-acetamido) and the Nd-UCNPs are activated by tissue-penetrating near-
infrared (NIR) light at 800 nm. Thus, simultaneous therapeutic NO delivery and photoluminescence (PL)
imaging can be achieved with a NIR diode laser source. The loaded microparticles are non-toxic to their
macrophage hosts in the absence of light. The microparticle-carrying macrophages deeply penetrate into
NIH-3T3/4T1 tumor spheroid models, and when the inﬁltrated spheroids are irradiated with NIR light, NO
is released in quantiﬁable amounts while emission from the Nd-UCNPs provides images of microparticle
location. Furthermore, varying the intensity of the NIR excitation allows photochemical control over NO
release. Low doses reduce levels of hypoxia inducible factor 1 alpha (HIF-1a) in the tumor cells, while high
doses are cytotoxic. The use of macrophages to carry microparticles with a NIR photo-activated
theranostic payload into a tumor overcomes challenges often faced with therapeutic administration of
NO and oﬀers the potential of multiple treatment strategies with a single system.
Introduction
Nitric oxide (NO) has exhibited signicant potential as a cancer
therapy, but its eﬀects are highly concentration- and location-
dependent.1 Furthermore, NO has a relatively short lifetime in
physiological media and induces signicant side eﬀects when
delivered systemically.2 Targeting strategies must be a key
feature for the delivery of any drug, and this is especially true for
a bioregulator such as NO. Photochemical uncaging allows one
to dene the location, timing and dosage of such drug delivery,
thus this technique has value as an investigative tool and for
addressing the progression of specic disease states.3–6 In this
context, we and others have developed photo-activated NO
releasing moieties (photoNORMs), since triggering with light
can provide precise spatial and temporal control of NO
delivery.7–10 However, this methodology is limited by the strong
wavelength dependence of light transmission through
tissue.11,12 Ultraviolet and shorter visible light are much less
tissue penetrating than are longer red or (ideally) near-infrared
(NIR) wavelengths. The ability of NIR light to transmit deeply
into tissue has inspired various approaches to designing pho-
toNORM systems including the engineering of molecular
compounds that are photoactive at longer wavelengths13,14 and
the use of antennas for multi-photon sensitization of NO release
with NIR light.15–18 However, delivering these conjugates to the
desired physiological targets continues to be a challenge.
It is diﬃcult to deliver the desired drug payload specically
to hypoxic areas of tumors via simple diﬀusion from the blood
stream, owing to poorly developed vascular structures.19–21
Instead it would be particularly valuable to utilize the inherent
biological mechanisms to facilitate such delivery. Tumor
hypoxia generates inammatory signals that recruit monocytes
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from the blood via chemotaxis, that once inside the tumor
diﬀerentiate into macrophages.22 This behavior has stimulated
interest in recruiting macrophages as carriers23–28 to localize
drugs in tumors at levels diﬃcult to attain with conventional
delivery methods.
The present study demonstrates the utility of macrophages
as carriers of micron-sized, poly(lactic-co-glycolic acid) (PLGA)
microparticles in which one can incorporate a theranostic
payload. The encapsulated payload here includes a photoNORM
that can be triggered for NO release by NIR light together with
Nd3+ doped upconverting nanoparticles (Nd-UCNPs) to provide
imaging capabilities.29,30 The BALB/c bone marrow derived
macrophages (BMMs) were shown to undergo phagocytosis of
these microcarriers. Such macrophages allow far deeper pene-
tration into large NIH-3T3/4T1 co-cultured tumor spheroids
(Scheme 1) than do the microparticles alone. Thus, as previ-
ously described by Clare and coworkers,23 such macrophages
have the potential to act as “cellular Trojan Horses” to carry
a therapeutic payload into tumors. It is shown here that, once
carried inside the spheroid by a BMM, the photoNORM in the
microparticles can be activated with NIR light to release NO. At
high light intensity, NO concentrations suﬃcient to cause direct
tumor cell cytotoxicity are generated, while at low light inten-
sity, the NO released leads to a signicant drop in the expres-
sion of hypoxia inducible factor HIF-1a in the tumor
microenvironment.
Results and discussion
NIR active photoNORM and Nd-UCNPs in microparticles
The cell-mediated delivery platform described here consisted of
murine BMMs loaded with polymer-based microcarriers into
which were incorporated a NIR sensitive photoNORM and NIR
active bioimaging Nd-UCNPs. The photoNORMwas prepared by
metathesis of the water-soluble salt [Mn(dpaqNO2)(NO)]ClO4
(dpaqNO2 ¼ 2-[N,N-bis(pyridine-2-yl-methyl)]-amino-N0-5-nitro-
quin-olin-8-yl-acetamido)13 with sodium tetraphenylborate to
give the corresponding, hydrophobic photoNORM
[Mn(dpaqNO2)(NO)]BPh4 (I). The hydrophobicity was needed to
minimize leakage of I from the polymer microcarrier into the
medium. The BPh4
 salt was further puried by recrystalliza-
tion to obtain black needles. Fig. 1 (top) shows the spectrum of I
in acetonitrile. Although the lmax of the longest wavelength
band is 650 nm, this absorbance extends to the NIR region
(3: 20.2 M1 cm1 at 794 nm) and overlaps with the output from
a 794 nm diode laser used as a continuous wave (CW) excitation
source in the present study. Direct 794 nm photolysis of I in
acetonitrile solution does indeed lead to NO release as
measured using the Sievers Nitric Oxide Analyzer (NOA) with
a quantum yield of 0.18 (ESI Fig. S1†).
The Nd-UCNPs were high quality core/shell upconverting
nanoparticles (Fig. 1, bottom) synthesized using the robotic
Workstation for Automated Nanocrystal Discovery and Analysis
(WANDA) of the Molecular Foundry at Lawrence Berkeley
National Laboratory.31–33 The host material for the 10 nm
Scheme 1 Illustration of macrophage cellular Trojan Horse strategy to
carry polymer based microparticles containing a photochemical
precursor of NO (photoNORM) plus upconverting nanoparticles
(UCNPs) into a tumor. NIR activation of the photoNORM/UCNP
combination releases NO to mediate the tumor environment in order
to facilitate various types of therapy as well as providing the oppor-
tunity for photoluminescence imaging.
Fig. 1 Top: absorption spectrum of [Mn(dpaqNO2)(NO)]BPh4 (I) in
acetonitrile. The red spike at the right is the spectrum of the 794 nm
diode laser. Bottom: TEM image of the core–shell the nano-particles
NaYF4:Yb/Gd/Nd/Tm (30/20/1/0.5%)@NaGdF4:Nd (20%). Inset:
upconversion emission spectrum of Nd-UCNPs under excitation by an
800 nm CW laser.
3730 | Chem. Sci., 2018, 9, 3729–3741 This journal is © The Royal Society of Chemistry 2018
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diameter cores was NaY0.8Gd0.2F4. (The Gd
3+ adduct favors the
hexagonal structure that typically gives higher upconversion
eﬃciency).§34–36 The host material was also doped with the
lanthanide ions Yb3+ (30%), Nd (1.0%) and Tm (0.5%). The 2 nm
thick shell was composed of NaGdF4 doped with Nd
3+ (20%).
The shell minimizes surface quenching eﬀects and improves
the luminescence eﬃciency of UCNPs. The Nd3+ sensitizers in
these NaYF4:Yb/Gd/Nd/Tm (30/20/1/0.5%)@NaGdF4:Nd (20%)
nano-particles (Nd-UCNPs) absorb NIR wavelengths near
800 nm allowing these materials to be excited at wavelengths
where the transmittance through water is most eﬃcient. Energy
absorbed by Nd3+ ions in the shell migrates via resonant
transfer to Nd3+ in the core and energy transfer to Yb3+ ions.36
The energy from multiple photons is transferred sequentially
from the excited Yb3+ dopants to Tm3+ emitters, thereby
producing upconverted photoluminescence (PL) bands in the
UV and visible range. The transmission electron microcopy
(TEM) and PL spectra of these Nd-UCNPs are shown in Fig. 1
(bottom).
The polymer-based microcarriers were prepared from PLGA
dissolved in dichloromethane (DCM) by a micro-emulsion
technique as described previously37,38 and in the Experimental
methods section (see below). The procedure simultaneously
encapsulated the photoNORM I and/or Nd-UCNPs into spher-
ical PLGA particles with ca. 1-micron diameter (0.35–2 mm) (ESI
Fig. S2 & S3†). The average loading of the manganese photo-
NORM was 4.36  0.66 wt% as determined by inductively
coupled plasma atomic emission spectroscopy (ICP-AES). The
spherical micro-particles have the optimal shape to facilitate
phagocytosis.39 The PLGA was acid terminated and the resulting
surface carboxylates were modied with immunoglobulin G
(IgG) by amide coupling in 0.1 M pH 5.5 2-(N-morpholino)
ethanesulfonic acid (MES) buﬀer to increase the eﬃciency of
phagocytosis. A bicinchoninic acid (BCA) protein assay indi-
cated there is ca. 44 mg of IgG per mg of PLGA particles.
NO release from photoNORM loaded polymer microparticles
Previous studies in these laboratories16,40 have shown that
UCNPs can serve as photosensitizers that absorb NIR photons
and emit visible light to trigger NO release from photoNORMs
that were not NIR sensitive. This process requires relatively high
intensity irradiation to eﬀect the multi-photon upconversion
mechanism of UCNPs and energy transfer from UCNPs to
photoNORMs. In the present case, the Mn photoNORM I is
photosensitive toward NO release via direct single-photon
excitation with 794 nm light, and this allows one to overcome
the scattering constraints that may be problematic for multi-
photon excitation in deeper tissue. However, since the extinc-
tion coeﬃcient for I at this wavelength is low (20.2 M1 cm1), it
was of interest to see whether the visible light generated by
upconversion from the Nd-UCNP would enhance NO release
owing to the signicantly higher extinction coeﬃcients of I in
the visible spectral region.
In order to test this possibility, microparticles of two
diﬀerent compositions were prepared. One contained both I
and Nd-UCNPs (PLGA-1), the other contained only the
manganese photoNORM I (PLGA-2). Data obtained from
dynamic light scattering (DLS) showed these two particle groups
to be similar in average size (1 micron, ESI Fig. S2† top), while
ICP-AES analysis showed the former to have somewhat higher
loading of I (4.76 wt% vs. 3.79 wt% respectively). Particles of
both types (0.5 mg) were separately suspended in 2.5 mL pH 7.4
phosphate buﬀered saline (PBS) solution and were irradiated
with a 794 nm diode laser while stirring and purging with
medical grade air. The purge gas was analyzed for NO using the
NOA for 1.0 s irradiation times at diﬀerent intensities
(in W cm2). The NOA signals recorded are shown in ESI
Fig. S3†while Fig. 2 plots the quantity of NO released from these
microcarriers in response to the diﬀerent excitation laser
intensities. Notably, both plots appear roughly linear over this
narrow range, consistent with a single photon excitation
mechanism for NO release. Additionally, the eﬃciencies of NO
release for PLGA-1 and PLGA-2 are 1.63 pmol W1 cm2 s1 and
2.06 pmol W1 cm2 s1 respectively. When diﬀerences in
loading are taken into account, this represents a lower NO
release from the Nd-UCNP loaded microparticles, although this
experiment is somewhat qualitative given that these are
suspensions of the microparticles. Nonetheless, under these
experimental conditions, the Nd-UCNPs have value primarily
for imaging purposes.
Microparticle uptake and compatibility
The goal of these experiments was to determine the amount of
loaded PLGA microparticles that can undergo phagocytosis into
the murine bone marrow macrophages that had been prepared
as described in the Experimental section (see ESI†). It has been
previously shown that rigid spheres, 1–3 microns in diameter,
are readily taken up by this mechanism.27,41,42 As noted above,
said microparticles were also surface modied with a covalently
bound layer of IgG to enhance uptake (ESI Fig. S4†). An
alamarBlue® cell viability assay was used to determine whether
Fig. 2 Plots of the NOA detected NO released vs. laser intensity
(W cm2) for the CW 794 nm photolysis of PBS suspensions of the
microcarriers PLGA-1 (black) and PLGA-2 (red).
This journal is © The Royal Society of Chemistry 2018 Chem. Sci., 2018, 9, 3729–3741 | 3731
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the microparticles proved toxic to the BMM cells. Fig. 3 shows
that these particles displayed no signicant acute toxicity for
concentrations as high as 100 mgmL1 for incubation periods of
24 and 48 h with BMMs. Moderate toxicity was observed at
higher concentrations. (Notably, a recent review of lanthanide-
UCNP toxicity has stated that, while there are numerous
reports of negligible or low toxicity, “there is a paucity of
knowledge concerning primary and secondary toxicity eﬀects on
the environment and humans.”)43 For the present study, the
microparticle concentration of 100 mg mL1 was selected for
further incubations. Analysis of BMMs containing NO-donor
loaded particles with ICP-AES determined an uptake of
0.667 mg manganese per 1  106 cells. This translates into 263
mg particles or 12.1 nano-equivalents of NO as photoNORM I in
106 cells.
Intracellular NO release
BMMs loaded with microparticles containing both I and Nd-
UCNPs (BMMp+) were then tested to verify internal release of
NO. The reporter was 4-amino-5-methylamino-20,70-diuoro-
uorescein diacetate (DAF-FM), which reacts to form a uores-
cent compound when exposed to intracellular NO. DAF-FM was
incubated with the BMMp+ macrophages and a control set of
BMMs without microparticles. Prior to DAF-FM incubation,
both sets were treated with L-N-nitroarginine methyl ester
(L-NAME), a nitric oxide synthase inhibitor, to reduce
background from biological NO production.44 Upon 794 nm
laser exposure at 13.0 W cm2 for 90 s, the BMMp+ set clearly
produced a visible uorescence response while the BMM set
without particles did not (ESI Fig. S5†).
Microparticle eﬀects on macrophage chemotaxis
The ability of macrophages to target tissue such as tumors is
governed by their ability to undergo chemotaxis towards sites of
inammation.22 Thus, it is crucial that the macrophages retain
this function aer drug loading. This question was probed
using a transendothelial assay (ESI Fig. S6†). First, monolayers
of bEnd.3 blood brain barrier (BBB) endothelial cells were
grown on FluoroBlok™ transwell inserts inside of the wells of
a 24-well plate asmodel endothelium barriers. Suchmonolayers
are very tight compared to those from other endothelial cells,
thereby making migration through the barrier challenging.45
Aer monolayer conuency, media containing 1  105
BMMp+ cells, media containing a comparable number of BMMs
without particles, and media alone were added to the tops of
separate transwells and the monocyte chemoattractant protein-
1 (MCP-1) was added below. Aer 24 h, the inserts were stained
with NucBlue® allowing for quantication of chemotaxis by
counting the nuclei of cells that had migrated to the bottom of
the insert using a uorescence microscope (corrected for the
signal from wells with a conuent monolayer to which only
media had been added). This analysis showedmigration of both
the native BMM cells and the BMMp+ cells across the endo-
thelium layers, although under these conditions, fewer of the
BMMp+ cells ((10.4  0.8)  103) migrated relative to the BMM
control cells ((17.1  2.4)  103). Thus, phagocytosis of micro-
particles did reduce chemotaxis as reported previously,27
although in the latter case an even sharper drop in chemotaxis
was observed. However, there are various strategies that can be
used to enhance overall macrophage recruitment and thera-
peutic eﬃcacy, if needed.28,46,47
Tumor spheroid penetration
In order to model a 3D tumor environment, tumor spheroids
were prepared from co-cultured murine NIH/3T3 broblast: 4T1
breast cancer cells with a 5 : 1 cell seeding ratio similar to that
used previously.48 Incorporation of broblasts into tumor
spheroids induces formation of a tumor stroma which
enhances spheroid compactness and increases the expression
of pro-inammatory cytokines used in leukocyte chemotaxis.49
With this seeding ratio, the hanging drop technique produced
spheroids with an average diameter of 962  60 mm (1.35 
105 cells per spheroid) aer 10 days of incubation with the
microparticle loaded macrophages introduced on day 7. These
spheroids are considerably larger than those produced with 4T1
cells alone (ESI Fig. S7†) as well as those NIH/3T3: 4T1 spher-
oids grown without the loaded BMM cells (ESI Fig. S8†), the
latter a likely result of macrophage supported tumor growth.49
Pimonidazole (PIMO) staining of the spheroids revealed
hypoxia throughout the spheroid interior. Considering that
hypoxia normally occurs 100–150 mm into a tumor,50 this is not
surprising.
Fig. 3 (a) Viability of BMMs with various particle incubation concen-
trations after 24 and 48 h. (b)–(d) Are slices of 4T1/NIH-3T3 co-
cultured breast tumor spheroids imaged by confocal microscopy. Blue
is 40,6-diamidino-2-phenylindole (DAPI) and red represents macro-
phages stained with CellTracker™ deep red. Green spots in (c) and (d)
are Cy-3–IgG labeled microparticles. (b) Spheroids stained with
a Hypoxyprobe™ Red549 to label hypoxia (cyan). (c) Spheroid incu-
bated with microparticles-laden BMMs. (d) Spheroid incubated only
with IgG modiﬁed PLGA microparticles.
3732 | Chem. Sci., 2018, 9, 3729–3741 This journal is © The Royal Society of Chemistry 2018
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Macrophages labeled with Celltracker™ deep red were used
to monitor the chemotactic penetration of the BMMp+ cells into
spheroids. Images of tumor spheroid center slices indicated
deep penetration (Fig. 3b), although the macrophages did not
reach the center but instead formed a visible ring around the
central section. Since oxygen is required for macrophage
chemotaxis, this behavior may reect a central necrotic region
with high hypoxia. Flow cytometry of spheroids dissociated with
Accumax™ demonstrated a macrophage cell composition of
0.53  0.4% or 715  540 macrophages per spheroid (ESI
Fig. S9†). Assuming that the BMMp+ retained their payload at
the concentration shown by ICP, these macrophages brought an
estimated 8.7 6.6 pico-equivalents of the photoNORM into the
spheroid. The value of the macrophages as “Trojan Horses” was
demonstrated using particles labeled with uorescent IgG.
Spheroid slices (Fig. 3c) demonstrated that macrophages with
internalized uorescent particles carried their payload into the
spheroids (Fig. 3c) but that IgG modied microparticles alone
were unable to penetrate more than a few cell layers when
incubated with the spheroids (Fig. 3d).
Nd-UCNP imaging
The Nd-UCNPs introduced to the polymer-based microparticles
provide an imaging agent that allows one to track the location of
these prodrug carriers and their macrophage hosts using tissue-
penetrating NIR excitation wavelengths. In addition, since their
chemotactic capacities allow macrophages to hone in on
inammation sites, the PL from UCNPs provides a potential
mechanism to detect hidden metastatic sites. Since I is photo-
activated by the same NIR wavelength, the combination of
this photoNORM and Nd-UCNP in these macrophage-carried
microparticles would provide theranostic capability.
Fig. 4 shows 3D images of spheroids incubated with BMMp+
or with BMMp and recorded with a confocal microscope using
a 808 nm laser source. The spheroids were labeled with calcein
AM to provide visualization of their periphery. PL signals were
noted from the spheroids treated with BMMp+ cells while those
treated with BMMp cells failed to produce a signal. These
luminescent emissions from the Nd-UCNPs provide a proof-of-
principle with regard to using UCNPs to track the macrophages,
but it is clear that either more eﬃcient emitters or (given that
the nonlinear relationship between UCNP PL and excitation
intensities) a more intense laser source may be needed for
in vivo diagnostic applications. On-going studies will address
this issue.
Photoactivated NO release inside spheroids
The next question was whether NO released by NIR excitation of
these BMMp+ inltrated spheroids can be detected externally
using the NOA, which to the best of our knowledge, would be
unprecedented. Five spheroids incubated with BMMp+ or
BMMs with PLGA-only particles (BMMp) were positioned in
the corner of a custom designed cuvette (Fig. 5a) containing
1 mL of Hank's Balanced Salt Solution (HBSS) solution. In
typical NOA analysis, the solution is entrained with the carrier
gas and stirred to facilitate transfer of NO to the detector.
However, such conditions would likely cause spheroid disas-
sembly and cell lysis. Instead, the spheroids were blanketed
with unstirred HBSS solution and irradiated with the 794 nm
diode laser operating at 13.1 W cm2 for specied time periods
(Fig. 5a). Subsequent gentle bubbling with medical-grade air
above the spheroids released NO from the solution without
disrupting the spheroids. The procedure could be repeated
Fig. 4 Z-stack two-photon confocal images (dimensions ¼ 508.4 mm
 508.4 mm) of live spheroids containing BMMs (left) with blank
particles and (right) with UCNP and NO-donor loaded particles.
Spheroids were stained with calcein AM (green). Particles were iden-
tiﬁed via emission (red) from embedded UCNPs with laser excitation at
810 nm and a pulse energy of 37.5 nJ. The wavelength range for
detection of UCNP emission was 420–460 nm.
Fig. 5 (a) The NIH/3T3:4T1 tumor spheroids in 1 mL Hank's buﬀered
salt solution (HBSS) under 794 nm laser irradiation (photo by Ping-Lin
Yang). Inset (up): a modiﬁed 1 mL cuvette for photolysis experiment of
cancer spheroids. Inset (down): the scheme represents that the
spheroids can be placed at the corner of the cuvette and exposed to
NIR laser excitation. (b) Up: NO released from ﬁve spheroids inﬁltrated
with bone marrow macrophages loaded with PLGA microparticles
containing I and Nd-UCNPs under 794 nm laser irradiation with 13.1 W
cm2. Down: the control experiment of six spheroids loaded with
PLGA microparticles. (c) Plot of NO detected vs. irradiation time. (d)
The viability of spheroids after 6, 12, or 18 min of laser exposure in
6min increments. Viability wasmeasured using a PNPP assay 24 h after
spheroid treatment. *p # 0.05 (Students t-test).
This journal is © The Royal Society of Chemistry 2018 Chem. Sci., 2018, 9, 3729–3741 | 3733
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several times with each sample (Fig. 5b and c). The NO released
photolysis from the ve BMMp+ inltrated spheroids aer the
6 min (total) was 13.6 pmol (2.7 pmol per spheroid (avg)). In
contrast, spheroids treated with BMMp cells gave no measur-
able NOA response. Based on volumes of1 mL, NO steady state
concentrations in excess of 1 mM were generated in the spher-
oids, a concentration exceeding that needed to induce p53
phosphorylation and/or nitrosative stress mediated apoptosis.1
The eﬀect of generating such high localized NO concentra-
tions was examined by evaluating cell viability aer 24 h using
a p-nitrophenyl phosphate (PNPP) assay.51 Fig. 5d illustrates the
results of irradiating spheroids containing BMMp+ or BMMp
cells with 794 nm light for 1 to 3 six-minute periods at
13.1 W cm2. In general, the data in Fig. 5d consistently show
reduced cell viability for irradiated spheroids inltrated with
BMMp+ cells relative to those loaded with BMMP cells, the
most convincing example being the 26% reduction for spher-
oids containing photoNORM loaded macrophages aer 12 min
irradiation compared to 6.6% reduction for similarly treated
BMMp loaded spheroids. However, the experimental uncer-
tainties are large and barely statistically signicant owing no
doubt to unavoidable variability in spheroid loadings and the
diﬃculty in preparing, photolyzing and analyzing a statistically
large number of loaded spheroids. Notably, the spheroids used
in this study were formed from 4T1 breast cancer cells, which
are p53 decient,52 so the observed damage can largely be
attributed to nitrosative stress induced apoptosis. Cancers with
p53 pathways are likely to be more sensitive to NO delivery at
these concentrations.
Low NO concentrations have been shown to produce bene-
cial shis in tumor microenvironment through reduction of
factors such as P-glycoprotein and HIF-1a that are implicated
in increased resistance to chemo- and radio-therapy.53–55 HIF-
1a is a transcriptional factor upregulated in hypoxia that
controls the expression of genes correlated with tumor cell
survival, metastasis, and angiogenesis.56 The eﬀect of gener-
ating lower NO concentrations on HIF-1a levels in the
tumor spheroids was examined by using LED excitation
(0.58 mW cm2 at 735 nm). Aer 8.5 h exposure, the spheroids
were dissociated into a single cell suspension. Cells were then
xed and labeled with anti-HIF-1a and by a uorescent
secondary antibody. Analysis with ow cytometry (Fig. 6)
revealed that the low intensity excitation at 735 nm reduced
proportion of cells expressing HIF-1a from 96.7  0.5% to 77.7
 8.7% in irradiated spheroids containing BMMp+ macro-
phages while spheroids with inltrated with BMMp macro-
phages showed little change in HIF-1a level upon excitation.
These data agree with previous studies demonstrating that low
concentrations of NO destabilize HIF-1a in hypoxia due to the
inhibition of cytochrome c oxidase,54 a critical component of
mitochondrial respiration. In a second trial, HIF-1a expression
in spheroids containing BMMp and BMMp+ macrophages
was shown by ow cytometry to be 90.3  5.1% and 62.2 
2.5%, respectively, aer LED excitation for 7 h (ESI Fig. S10†),
thus conrming the impact on this proliferative factor upon
delivering a low concentration of NO.
Summary
These studies demonstrate that the timing and dosage of NO
release from photoNORM loaded microparticles can be
controlled inside tumor models by triggering with tissue
penetrating NIR light. Bone marrow derived macrophages serve
as Trojan Horse carriers for the polymer-based microparticles
incorporating both the photoNORM (I) and Nd3+-doped
upconverting nanoparticles for therapeutic and imaging appli-
cations. In this manner, the carrier macrophages load large
quantities of a photoactivated therapeutic agent without
signicant eﬀects on viability. The loaded BMMp+ cells main-
tain the chemotactic ability to traverse an in vitro brain blood
barrier transendothelial model and to penetrate tumor spher-
oids with their photoactive cargos. Such penetration does not
occur with the microparticles alone. However, while the tumor
spheroids provide a valuable proof-of-principle, in vitro model
to demonstrate that macrophages can inltrate and deliver
a payload to such tissues, the next stage will be to demonstrate
such targeting in vivo. In this context we are encouraged by
a recent study57 where blood monocytes loaded with nano-sized
Fig. 6 Top: ﬂow cytometry analysis of dissociated tumor spheroids
stained for HIF-1a under diﬀerent treatments. Gated cells correlate
with a positive signal from staining. (i) and (ii) Three runs of analysis for
spheroids loaded with PLGA microparticles incorporating I and Nd-
UCNPs with and without 735 nm LED irradiation at 0.58 mW cm2 for
8.5 h. (iii) The comparison of (i) and (ii) for each run. Red and black lines
represent particles with and without light irradiation respectively.
Bottom: the summary of ﬂow cytometry analysis for the control (i) and
the NO release study (ii).
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polymeric micelles containing paclitaxel (PTX) were used to
treat metastatic breast cancer in mice. Such PTX delivery was
signicantly more eﬃcient than using free PTX or PTX loaded
nanoparticles alone.
Both I and the Nd-UCNPs are excited with NIR light at
800 nm, the ideal wavelength for tissue transmission. Thus,
the Nd-UCNP emission is used to visualize BMMp+ cells inl-
trated into spheroids while NIR photoactivation of I released
NO. We demonstrate two types of potentially therapeutic eﬀects
by using diﬀerent light intensities to irradiate the BMMp+ cell
inltrated tumor spheroids. The micromolar NO concentration
generated by high intensity NIR laser excitation leads to
increased nitrosative stress and cell mortality. In contrast, lower
concentrations of NO served to modify the tumor microenvi-
ronment by destabilizing HIF-1a. Although not explored in the
current study, it should be noted that targeted NO release in the
hypoxic regions of tumors should enhance the eﬀectiveness of
cancer chemotherapy55 and radiotherapy.58,59 In these contexts,
macrophage-mediated delivery of photoNORMs combined with
NIR excitation represents a fresh approach that allows one to
target tumors or other diseased tissues characterized by
inammation. This strategy will facilitate the spatially and
temporally controlled release of NO or of other caged
compounds for precise therapeutic applications.
Experimental section
Materials
All cell lines (4T1, NIH-3T3, and bEnd.3) were purchased from
ATCC. BALB/c mice (6–8 weeks old) were purchased from
Charles River. Sodium tetraphenylborate, sodium tri-
uoroacetate, sodium oleate, ammonium uoride, lanthanide
chlorides (99.9+%), oleic acid (OA) (90%), 1-octadecene (ODE)
(90%), poly(vinyl) alcohol (PVA, Mw: 13 000–23 000), 4-mor-
pholineethanesulfonic acid (MES, lowmoisture content, 99+%),
immunoglobulin G (IgG from mouse serum), N-(3-dimethyla-
minopropyl)-N0-ethylcarbodiimide hydrochloride (EDC$HCl,
commercial grade), Triton™ X-100 (BioXtra), Tween® 20 (Bio-
Xtra), agarose (BioReagent), sodium hydroxide (NaOH, ACS
reagent grade), sodium acetate (RegentPlus®), puried human
plasma bronectin (1 mg mL1), and Perfecta3D® 96-well
hanging drop plates were purchased from Sigma-Aldrich. 10
PBS (OmniPur® liquid concentrate) was purchased from EMD
Millipore. Poly(lactic-co-glycolic acid) (5050 DLG 8A, acid
terminated) was purchased from Lakeshore Biomaterials. 4-
Amino-5-methylamino-20,70-diuorouorescein diacetate (DAF-
FM-2DA, Molecular Probes®) was purchased from Life Tech-
nologies. N-Hydroxysuccinimide (NHS), fetal bovine serum
(FBS), Dulbecco's Modied Eagle Medium high glucose
(DMEM), Dulbecco's Modied Eagle Medium: Nutrient mixture
F12 GlutaMAX™ and high glucose (DMEM/F12), sodium pyru-
vate solution (100 mM), penicillin streptomycin 10 000 U mL1
(P/S), trypsin/EDTA (0.25%), Hank's Balanced Salt Solution
without calcium andmagnesium (HBSS), Dulbecco's Phosphate
Buﬀered Saline without calcium and magnesium (DPBS),
NucBlue®, CellTracker™ deep red, goat serum, FITC labeled
goat-anti-rabbit, rabbit anti-HIF-1a, p-nitrophenyl phosphate
(PNPP) substrate tablets, calcein AM, micro bicinchoninic acid
assay kit, and alamarBlue® was purchased from Thermo Fisher
Scientic. All TC and Non-TC treated plasticware for cell
culture, and Fluoroblok™ transwell inserts were purchased
from Corning. Bambanker™ cell freezing media was purchased
from Bulldog Bio. Accumax™ was purchased from Innovative
Cell Technologies. L-N-Nitroarginine methyl ester hydrochloride
salt (L-NAME) was purchased from Caymen Chemical. Murine
monocyte colony stimulating factor 1 (MCSF-1) and murine
monocyte chemoattractant protein 1 (MCP-1) were purchased
from Peprotech. Hypoxyprobe-Red549 Kit containing pimoni-
dazole HCl and mouse Dylight™ 549-Mab was purchased from
Hypoxyprobe. Immunoglobulin G labeled with Cyanine 3.5
(Cy3.5–IgG) was purchased from Jackson Immuno.
The [Mn(dpaqNO2)(NO)]BPh4 salt (I) was prepared under
reduced lighting by anion metathesis of the perchlorate analog
that had been synthesized as reported.13 [Mn(dpaqNO2)(NO)]
ClO4, (119.3 mg, 0.195 mmol) was dissolved in 3 mL solution of
1 : 1 acetonitrile/deionized (DI) water that was then added to
a 2 mL volume of acetonitrile (ACN) in which was dissolved
NaBPh4 (66.7 mg, 0.195 mmol). The resulting mixture was
sonicated for 3min aer whichmost of the solvent was removed
under reduced pressure. The resulting hydrophobic black solid
was suspended in aqueous solution then collected by ltration,
washed with DI water and dried under vacuum. The solid was
then dissolved in dichloromethane (DCM) and recrystallized by
vapor diﬀusion of ether to produce crystalline black needles of I.
IgG-modied microcarriers
The procedure for forming the polymer micro-emulsions was
modied from the literature.37–39 Acid-terminated PLGA
(100 mg) and 80 mL of a solution of Nd-UCNPs in hexane
(10 mg UCNPs) were added into 500 mL DCM, and the mixture
was sonicated for 45 min at room temperature. A 14 mg sample
of I was dissolved in a mixture of ACN (150 mL) and DCM
(400 mL) to form a dark purple solution that was then trans-
ferred into the PLGA solution, and the mixture was sonicated
until homogenous. If the volume of as-prepared solution was
lower than 1.1 mL, more DCM was added. The polymer solution
was slowly added into 200 mL of 1 wt% polyvinyl alcohol (PVA)
aqueous solution contained in a 250 mL half-spherical
container while the ultrasonic homogenizer was turned to 350
watts for 30 s. A dark brown colloidal solution formed imme-
diately. The ask containing the colloidal suspension was fully
covered with aluminum foil and stirred overnight to evaporate
the volatile organic solvents. Themilky solution was centrifuged
to collect a solid, which was washed with 18megohm pure water
to remove the PVA. Following particle purication, the brown
pellet was re-suspended in 45 mL pure water and then the
1-micron particles were separated by diﬀerent centrifuge speed
(4000 rpm to remove particles <500 nm and 300 rpm to remove
particles size >3 mm). The resulting particles were dried under
vacuum and re-suspended in 0.1 M pH 5.5 MES buﬀer solution
with the concentration of 1 mg mL1. EDC$HCl (70.94 mmol
per 1 mg particles) and NHS (106.87 mmol per 1 mg particles)
were added into the colloidal MES solution, which was then
This journal is © The Royal Society of Chemistry 2018 Chem. Sci., 2018, 9, 3729–3741 | 3735
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sonicated at room temperature for 30 min. Subsequently, 10 mL
IgG solution (11.21 mg mL1) per 1 mg microparticles was
added and the mixture stirred overnight. The IgG modied
particles were collected by centrifugation and washed with
18 megohm pure water at least three times. IgG concentration
was determined with a micro BCA assay according to the
manufacturer's instructions. Aer incubation, particles were
removed from solution with centrifugation to avoid light
scattering during absorbance measurements.
Initially, a beaker was utilized during the emulsion process,
however; better yields were obtained using a half-spherical glass
ash, since there are no corners in the latter and the sonic
energy is distributed equally preventing settling and allowing
more of the PLGA to form particles of the correct size.
Bone marrow macrophage preparation and other cell cultures
Bone marrow was harvested from 6–8 week old BALB/c mice in
accordance with previously published methods.60 Experiments
were performed in compliance with all United States federal
and California state regulations governing the humane care and
use of laboratory animals, including the USDA Animal Welfare
Act (Registration #: 93-R-0438) and the PHS Policy on Humane
Care and Use of Laboratory Animals (PHS Assurance # A3865-
01) and were reviewed and approved by the University of Cal-
ifornia Santa Barbara Institutional Animal Care and Use
Committee as part of protocol 6-16-916. Aer marrow isolation,
cells were then suspended in a 90% FBS/10% dimethyl sulfoxide
(DMSO) and frozen for later use according to previous reports.61
Unless otherwise specied, all culture ware used with macro-
phages was non-TC treated plastic. Bone marrow macrophages
were produced via slight modication of previously published
methods.60 Cryo-preserved bone marrow was thawed and added
to 10 mL of DMEM/F-12 media supplemented with 10 mM Glu-
taMAX™, 10% FBS, 1000 U mL1 P/S, and 20 ng mL1 MCSF-1
(media denoted as DMEMb) cells were centrifuged at 400 g for
10 min, resuspended in DMEMb at 2.3  106 live cells per mL.
DMEMb (24 mL) and 1 mL of bone marrow were added to a ask
and put in the incubator for 7–8 days to allow the bonemarrow to
mature into BMMs. On day 3, 25 mL of additional DMEMb was
added to each ask to replenish the MCSF-1 in solution. Aer
cells had matured into BMMs, DMEMb was removed from the
ask and cells were washed with DPBS. To dislodge the cells, the
ask was treated with ice cold Accumax™ (10–15 mL) for 20–
30 min, and thumped once with the palm of the hand. Cells were
collected, washed with DMEMb and centrifuged at 400 g for
10 min. Cells were resuspended in Bambanker™ cell cryopres-
ervation media at 5  106 cells per mL. BMMs were kept at
80 C overnight and were transferred to liquid nitrogen aer-
wards. Conrmation of macrophage maturation was done using
CD11b staining as described by Zhang et al.60
For experiments, BMMs were thawed and added to non-TC
treated dishes for 24 h. Cells were then detached with
Accumax™ and counted. These cells were then replated at 62 500
BMM per cm2 on plastic ware 18 h prior to the experiment.
NIH-3T3 murine broblast cells, 4T1 murine breast cancer
cells, and bEnd.3 murine brain endothelial cells between
passage 3–15 were cultured on TC-treated plastic ware with
Dulbecco's modied eagle medium (DMEM) supplemented
with 10% fetal bovine serum (FBS), 1000 U mL1 of penicillin/
streptomycin (P/S) and 1 mM sodium pyruvate (media mixture
known as DMEMpy). Cells were passaged with 0.25% trypsin/
EDTA once they reached a conuency of >80%.
Tumor spheroids
Tumor spheroids were grown with a procedure based on
previous research.48 Conuent plates of 4T1 and NIH-3T3 cells
were split and resuspended in DMEMpy and then mixed at
a ratio of 1 : 5 4T1 : NIH-3T3 at a total cell concentration of
1.11  104 cells per mL. To prevent evaporation of the hanging
drops, the liquid reservoirs on 96 well hanging drop plates from
3d Biomatrix were lled with hot 0.5% w/v agarose and allowed
to cool to room temperature. A 45 mL aliquot of the cell mixture
was added to the top of each well. Plates were sealed with Par-
alm® and put in the cell incubator for 7 days. Media was
replenished on days 4 and 6 by removing 15 mL of media from
each droplet and adding 15 mL of fresh DMEMpy. This proce-
dure was done 2 times in a row during each media change
instead of removing 30 mL of media all at once which can
compromise the droplet. Spheroids were grown in droplets for
7 days.
To incorporate macrophages, spheroids were transferred
into 200 mL 96 well PCR plates used to allow for their easy
manipulation and inversion on the rotisserie without spilling.
Spheroids were washed 3 times with 100 mL of DMEMpy.
DMEMpy (50 mL) was added to each spheroid aer the nal
wash. A 50 mL aliquot of a solution of BMMs with blank or NO-
donor loaded particles at 4  105 cells per mL in DMEMpy was
added to each spheroid. Plates were put on a rotisserie in a cell
incubator for 3 days to assure optimal interaction between
macrophages and spheroids. On day 1.5, 100 mL of additional
DMEMpy was added to each spheroid to replenish solution
nutrients. Aer 3 days, spheroids were washed 3 times with
DMEMpy to remove macrophages that had failed to inltrate
the spheroid. Spheroids were then used for various downstream
applications.
Particle loading into BMMs
Particles with or without NO-donor and UCNPs in DI water at
a concentration of 5 mg mL1 in a glass vial were sonicated for
10 min to break up particle aggregates. A volume of 340 mL of
the microparticle solution was added to macrophages plated at
62 500 cells per cm2 in a 100 mm diameter non-TC treated Petri
dish in 17 mL of DMEMb to make a 100 mg mL1 solution.
Dishes were put in a culture incubator for 2 h to allow for
phagocytosis. Cells were washed once with warm DPBS aer
which, ice cold Accumax™ (5 mL) was added and incubated at
37 C for 15–30 min. Cells were then pipetted up and down
gently to release them from the plate. DMEMb (5–7 mL) was
added to the cell suspension. Cells were centrifuged once at
400 g for 10 min and resuspended in 2 mL DMEMb. Cells were
then centrifuged 3 times at 42 g for 5 min to remove free
particles in solution. In cases where macrophage tracking was
3736 | Chem. Sci., 2018, 9, 3729–3741 This journal is © The Royal Society of Chemistry 2018
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desired, 2 mM CellTracker™ deep red in serum free DMEMb
was added to cells for 45 min before Accumax™ was applied.
Quantication of particle loading and macrophage uptake
Particles of a known concentration containing the NO-donor
and UCNPs were digested in 1 : 3 HNO3 : HCl for 24 h to
assure all manganese was completely dissolved. Inductively
coupled plasma atomic emission spectroscopy (ICP-AES) was
conducted with a Thermo iCAP 6300 and was used to measure
the manganese content of each sample. Samples were
compared tomanganese standard. For quantication of particle
uptake, 3  106 cells with particles were analyzed in the same
manner. These cells were compared to cells without particles.
Macrophage-particle compatibility
Macrophages loaded with microparticles as described above
with various particle incubation concentrations were plated at
62 500 cells per cm2 in 96 well plates in 100 mL DMEMb. Cells
were put in a cell incubator and le for 24 or 48 h. A mixture
containing 100 mL of DMEMb and 20 mL of alamarBlue® was
added to the media in each well. The plate was incubated for
3.5 h. A volume of 110 mL of each well was transferred to black
bottomed well plates to improve the sensitivity of the uores-
cence measurement. Solution uorescence was measured on
a TECAN M220 Innite Pro plate reader (lex ¼ 550 nm, lem ¼
590 nm). Fluorescence from wells without cells was subtracted
as baseline.
Qualitative determination of NO release
Human bronectin at 150 mg mL1 in DPBS was added to glass
confocal dishes and incubated for 2 h at 37 C to improve its cell
adhesion properties. Wells were washed 3 times with DPBS.
Macrophages with particles were plated in the glass confocal
dishes at 62 500 cells per cm2 and incubated for 8 h in
DMEMpy. Cells were incubated with L-NAME at 75 mg mL1 in
DMEMpy for 1 h to inhibit biological NO production from nitric
oxide synthases. Wells were aspirated and 9.3 mM 4-amino-5-
methylamino-20,70-diuorourescein (DAF-FM-2DA), a dye that
detects intracellular NO release, with L-NAME in DMEMpy was
added to the cells and incubated for 1 h. Wells were washed ve
times with phenol red free, FBS free DMEMpy with L-NAME to
remove uninternalized DAF-FM. Wells were exposed to
a 794 nm laser for 90 s at 13.1 W cm2. NucBlue® was added to
the wells to label cell nuclei. Wells were imaged 20 min later.
Images were taken with an Olympus Fluoview 1000 Spectral
Confocal. Care was taken to image cells as quickly as possible to
prevent the release of extra NO. Samples were compared to
macrophages exposed to the laser without particles.
Quantication of macrophage chemotaxis
Human bronectin (50 mL, 150 mg mL1) in DPBS was added to
the top of 24-well sized FluoroBlok™ transwell inserts with 8
mm pores and incubated in a cell incubator for 1.5–2 h to
improve their adhesion properties for endothelial cells. The top
of the inserts was washed 3 times with 200 mL of DMEMpy. A
200 mL aliquot of bEnd.3 cells at a concentration of 1  105
cells per mL were added to the top of each well. Cells were
incubated for 4.5 days with media changes every other day. No
media was added to the bottom of the insert until the nal day
to prevent the growth of a monolayer in the bottom of the insert
which has been reported previously when media is added to
both sides.62 On day 4.5, media in the top insert was replaced
and 600 mL of DMEMpy was added to the bottom of the insert.
Transepithelial electrical resistance (TEER) values were taken
and all inserts with a value $0.33 U cm2, which traditionally
represents a fully conuent monolayer, were accepted for the
experiment. Inserts were washed 3 times with DMEMpy. 200 mL
of either DMEMpy alone, or BMMs with or without particles at
5  105 cells per mL in DMEMpy were added to the top of the
inserts and 600 mL of DMEMpy with 125 ng mL1 MCP-1 was
added to the bottom of each well to serve as a chemoattractant
for the macrophages. Cells were incubated for 24 h in a cell
incubator and washed once with DPBS. NucBlue® in HBSS was
added to the top and bottom of each insert to visualize cells.
Aer 20 min, images from 3 random locations from the bottom
of each insert were taken with an Olympus CKX-41 inverted
microscope. Cells were counted with the particle analysis tool on
ImageJ. Wells that contained only a bEnd.3monolayer were used
as a baseline and were subtracted out of macrophage wells.
Determination of macrophage/spheroid penetration
Macrophages labeled with CellTracker™ deep red were allowed
to penetrate spheroids as described above to allow for visuali-
zation. Spheroids were xed in ice-cold methanol for 30 min.
Spheroids were then embedded in Tissue-Tek® O. C. T.
compound and sectioned with a 25 mm thickness. Spheroids
were mounted with Vectashield® hard set mountingmedia with
4,6-diamidino-2-phenylindole (DAPI) to preserve samples and
stain cell nuclei. For hypoxia detection, some spheroids were
incubated with 100 mM PIMO in DMEMpy for 2 h prior to xa-
tion with methanol (MeOH). This allowed PIMO to fully inl-
trate spheroids and covalently bind to cells in hypoxic regions.
Aer sectioning, these samples were blocked with PBS con-
taining 4% FBS, 1% goat serum, and 0.05% Tween® 20
(blocking solution) for 1 h. Hypoxyprobe Red549 (#HP7-100Kit;
Hypoxyprobe) in a 1 : 200 dilution in blocking solution was
added to each spheroid for 18 h at 4 C to allow the antibody to
bind to the PIMO present in the sectioned spheroid. Sections
were then washed three times with PBS with 0.05% Tween® 20.
In other experiments to demonstrate retention of particles aer
spheroid penetration, particles were labeled with Cy3.5®–IgG.
Because of the overlap between Hypoxyprobe Red549 and
Cy3.5®, they were not used together. Images were acquired with
an Olympus Fluoview 1000 spectral confocal microscope and
processed with ImageJ.
NO release measurement
The NO measurement followed the modied procedure from
the literature.16 All spheroids were carefully transferred to 1 mL
HBSS solution in a modied cuvette and closely placed at the
corner in order to get full exposure with a 794 nm diode laser.
This journal is © The Royal Society of Chemistry 2018 Chem. Sci., 2018, 9, 3729–3741 | 3737
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Medical-grade air was purged into the cuvette through plastic
tubing but not directly purged into the solution. Laser intensity
13.1W cm2 was applied to all spheroid-involvedmeasurement.
During the period of laser irradiation on these spheroids, the
medical air purging was only above the solution. But once the
irradiation was stopped, the purging tubing was manually
immersed into the solution carefully in order to avoid agitating
these spheroids. The owing gas conveyed the NO released to
the NOA.
Confocal imaging of UCNPs in live tumor spheroids
Spheroids were grown and incubated with macrophages with
and without particles as described in a previous section. Calcein
AM (10 mM) was incubated with the spheroids for 2 h in
DMEMpy and to mark spheroid peripheries. Live spheroids
were added to a Petri dish with HBSS. UCNPs were detected
using a 3 W 100 fs pulsed laser (37.5 nJ per pulse) operating at
810 nm. Images were acquired with an Olympus Flowview
1000MPE confocal microscope with a 25 objective (numerical
aperture ¼ 1.05). Images were recorded over a 508.431 mm 
508.431 mm area (1024  1024 pixels) and were acquired with
a scan rate of 100 ms per pixel. Bandpass lters (420–460 nm and
495–540) nm were utilized to isolate uorescence from UCNPs
and calcein AM, respectively. Images acquired every 10 mmwere
combined to form 3D reconstructions with ImageJ.
Tumoricidal potential of high dose NO therapy
Five spheroids containing microparticle loaded macrophages
with and without NO-donor were transferred to the corner of
a cuvette containing DMEMpy. Spheroids were exposed to
a 794 nm laser at 13.1 W cm2 for 6 min to release NO from
particles inside macrophages in the spheroids. This procedure
was done to each spheroid 1, 2, or 3 times with 2 min between
each exposure. The spheroids were transferred to a 96 TC-
treated well plate and incubated for 24 h. Aer incubation,
media was removed and 100 mL of DPBS was added to each well.
To measure spheroid viability, a PNPP assay was used as
previously described with slight modications.51 Briey, one
10 mg PNPP substrate tablet was added to 5 mL of a solution
containing 0.1 M sodium acetate and 0.1% Triton™ X-100. A
100 mL aliquot of this solution was added to the DPBS already in
each well. The plate was incubated at 37 C for 3–3.5 h. NaOH
(10 mL, 1 M) was added to each well aer which absorbance was
measured at 405 nm on a TECAN M220 Innite Pro plate reader
within 10 min of NaOH addition to prevent loss of signal.
Tumor microenvironment modulation with low dose NO
therapy
Spheroids with particle loadedmacrophages were transferred to
a 96 well TC-treated plate with a pipette and were incubated for
12 h to allow them to adhere. Half of the spheroids were then
exposed to a 735 nm LED at 0.58 mW cm2 for 8.5 h. Spheroids
were collected in groups of 6 and washed once with DPBS.
Accumax™ (300 mL) was added and spheroids were incubated
for 30–45min. Spheroids were broken up with rapid pipetting to
form a single cell suspension. Cells were xed with 4%
paraformaldehyde (PFA) for 10 min followed by permeabiliza-
tion with ice cold methanol (MeOH) for 10 min to allow for
antibody labeling. Cells were washed three times with DPBS
with 1% BSA and 0.1% Tween 20. Rabbit anti-HIF-1a (1 : 100,
#PA1-16601; ThermoFisher Scientic) in 1% w/v BSA and 0.1%
Tween 20 was added to the cells for 1 h at RT. Cells were washed
once with DPBS with 1% BSA and 0.1% Tween 20. FITC labeled
goat-anti-rabbit IgG (H + L) (1 : 250, #A27034; ThermoFisher
Scientic) was added to the cells for 30 min in DPBS with 1%
BSA and 0.1% Tween 20. Cells were washed with DPBS 3 times
and analyzed via ow cytometry on a FACSAria (Becton Dick-
inson) using 488 nm (HIF-1a) or 633 nm (CellTracker Deep Red)
excitation. Cells were analyzed for % of the cells with uores-
cence signal greater than background by setting the gate to
exclude the signal from unstained cells (negative control).
Results were analyzed with FCM Express 6 Plus.
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for synthetic convenience, since the only function Gd3+ serves is to facilitate
synthesis of the desired hexagonal phase of NaYF4 (ref. 34–36). There are other
methods for synthesizing hexagonal NaYF4 without Gd (ref. 33), and these will be
used in future studies.
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